Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | DHPS | P49366 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4723071 | 0.84 | F10 (0.55) | ALDH1A1MAPTHDAC8HDAC6PPARG | |
| SCHEMBL7292373 | 0.80 | NR1H4 (0.55) | NR1H4HDAC3HDAC11HDAC8HDAC6 | |
| SCHEMBL1687866 | 0.79 | NR1H4 (0.67) | NR1H4ALDH1A1MAPTHDAC3HDAC11 | |
| SCHEMBL21588677 | 0.75 | HDAC3 (0.69) | NR1H4ALDH1A1MAPTHDAC3HDAC11 | |
| SCHEMBL4720399 | 0.74 | MEN1 (0.53) | NR1H4ALDH1A1MAPTKCNK3RAB9A | |
| SCHEMBL5223950 | 0.73 | NR1H4 (0.71) | NR1H4PPARGPPARANPC1RAB9A | |
| SCHEMBL4724325 | 0.73 | RAB9A (0.49) | ALDH1A1MAPTPPARGPPARAKCNK3 | |
| SCHEMBL7291713 | 0.73 | NPC1 (0.79) | NR1H4MAPTHDAC3HDAC11HDAC8 | |
| SCHEMBL1687867 | 0.73 | NPC1 (0.79) | NR1H4MAPTHDAC3HDAC11HDAC8 | |
| SCHEMBL7293746 | 0.73 | NPC1 (0.79) | NR1H4MAPTHDAC3HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928843-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007024754-A1 | BIS-ARYL UREA COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE-MEDIATED DISEAES | AMGEN INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | AMGEN INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049592-A1 | Bis-aryl urea compounds and methods of use | TIE1, KDR, BDKRB2 | NR1H4 862/4885ALDH1A1 1489/4885MAPT 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.